Author/Authors :
Adebimpe W. Kasumu، نويسنده , , Charlotte Hougaard، نويسنده , , Frederik Rode، نويسنده , , Thomas A. Jacobsen، نويسنده , , Jean Marc Sabatier، نويسنده , , Birgitte L. Eriksen، نويسنده , , Dorte Str?b?k، نويسنده , , Xia Liang، نويسنده , , Polina Egorova، نويسنده , , Dasha Vorontsova، نويسنده , , Palle Christophersen، نويسنده , , Lars Christian B. R?nn، نويسنده , , Ilya Bezprozvanny، نويسنده ,
Abstract :
Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disorder caused by a polyglutamine expansion within the Ataxin-2 (Atxn2) protein. Purkinje cells (PC) of the cerebellum fire irregularly and eventually die in SCA2. We show here that the type 2 small conductance calcium-activated potassium channel (SK2) play a key role in control of normal PC activity. Using cerebellar slices from transgenic SCA2 mice we demonstrate that SK channel modulators restore regular pacemaker activity of SCA2 PCs. Furthermore, we also show that oral delivery of a more selective positive modulator of SK2/3 channels (NS13001) alleviates behavioral and neuropathological phenotypes of aging SCA2 transgenic mice. We conclude that SK2 channels constitute a therapeutic target for SCA2 treatment and that the developed selective SK2/3 modulator NS13001 holds promise as a potential therapeutic agent for treatment of SCA2 and possibly other cerebellar ataxias.
